Amicus Therapeutics
Stock Forecast, Prediction & Price Target
Amicus Therapeutics (FOLD) stock Price Target by analysts
$15
Potential upside: 106.89%
Amicus Therapeutics price prediction
What is Amicus Therapeutics stock analysts` prediction?
Amicus Therapeutics stock forecast: Based on 1 Wall Street analysts` predicted price targets for Amicus Therapeutics in the last 3 months, the avarage price target is $15, with a high forecast of $NaN. The average price target represents a 106.89% change from the last price of $7.25.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Amicus Therapeutics stock Price Target by analysts
Full breakdown of analysts given Amicus Therapeutics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Tazeen Ahmad Bank of America Securities | 0% 0/1 | 11 months ago | $15 106.89% upside | $12.03 | StreetInsider | Previous targets (0) |
Debjit Chattopadhyay Guggenheim | 0% 0/1 | over 1 year ago | $13 79.31% upside | $9.04 | TheFly | Previous targets (0) |
Jeffrey Hung Morgan Stanley | 0% 0/2 | over 1 year ago | $19 162.06% upside | $9.48 | StreetInsider | Previous targets (1) |
Jeffrey Hung Morgan Stanley | 0% 0/2 | almost 2 years ago | $20 175.86% upside | $12.66 | StreetInsider | Previous targets (1) |
Salveen Richter Goldman Sachs | 100% 1/1 | over 4 years ago | $14 93.10% upside | $9.39 | StreetInsider | Previous targets (0) |
Amicus Therapeutics Financial Estimates
Amicus Therapeutics Revenue Estimates
Amicus Therapeutics EBITDA Estimates
Amicus Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $305.51M N/A | $329.23M 7.76% | $399.35M 21.29% | Avg: $641.91M Low: $612.01M High: $701.77M avg. 60.73% | Avg: $841.40M Low: $813.99M High: $881.95M avg. 31.07% | Avg: $1.05B Low: $1.02B High: $1.11B avg. 25.88% | Avg: $1.27B Low: $1.23B High: $1.33B avg. 20.20% |
Net Income
% change YoY
| $-250.46M N/A | $-236.56M 5.54% | $-151.58M 35.92% | Avg: $65.11M Low: $8.85M High: $156.43M avg. 142.95% | Avg: $211.34M Low: $106.25M High: $295.16M avg. 224.55% | Avg: $363.05M Low: $347.68M High: $385.79M avg. 71.78% | Avg: $529.32M Low: $506.91M High: $562.49M avg. 45.79% |
EBITDA
% change YoY
| $-196.10M N/A | $-191.88M 2.15% | $-92.07M 52.01% | Avg: $-421.15M Low: $-460.42M High: $-401.53M avg. -357.38% | Avg: $-552.03M Low: $-578.63M High: $-534.05M avg. -31.07% | Avg: $-694.95M Low: $-728.44M High: $-672.31M avg. -25.88% | Avg: $-835.40M Low: $-875.66M High: $-808.19M avg. -20.20% |
EPS
% change YoY
| -$0.92 N/A | -$0.82 10.86% | -$0.51 37.80% | Avg: $0.21 Low: $0.03 High: $0.53 avg. 141.15% | Avg: $0.72 Low: $0.36 High: $1 avg. 243.13% | Avg: $1.23 Low: $1.18 High: $1.31 avg. 70.78% | Avg: $1.79 Low: $1.72 High: $1.91 avg. 45.79% |
Operating Expenses
% change YoY
| $470.96M N/A | $495.06M 5.11% | $427.65M -13.61% | Avg: $449.17M Low: $428.25M High: $491.06M avg. 5.03% | Avg: $588.77M Low: $569.59M High: $617.14M avg. 31.07% | Avg: $741.19M Low: $717.05M High: $776.92M avg. 25.88% | Avg: $890.99M Low: $861.97M High: $933.93M avg. 20.20% |
FAQ
What is Amicus Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 121.27% in 2025-2028.
We have gathered data from 8 analysts. Their low estimate is 8.85M, average is 65.11M and high is 156.43M.
What is Amicus Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 34.47% in 2025-2028.
We have gathered data from 9 analysts. Their low revenue estimate is $612.01M, average is $641.91M and high is $701.77M.
What is Amicus Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 125.21% in 2025-2028.
We have gathered data from 8 analysts. Their low earnings per share estimate is $0.03, average is $0.21 and high is $0.53.
What is the best performing analyst?
In the last twelve months 1 analysts have been covering Amicus Therapeutics stock. The most successful analyst is Tazeen Ahmad.